Randomized Experiment Evaluation Algorithm

Context:
- It can range from being a Categorical Outcome Randomized Experiment Analysis Algorithm to being a Continuous Outcome Randomized Experiment Analysis Algorithm.
- It can range from being an Individual Randomized Experiment Analysis Algorithm to being a Cluster Randomized Experiment Analysis Algorithm.
Example(s):
- a Randomized Experiment with Baseline and Post-Treatment Measures Evaluation Algorithm.
See: Randomized Experiment Analysis System.

References

http://en.wikipedia.org/wiki/Randomized_controlled_trial#Analysis_of_data_from_RCTs
- The types of statistical methods used in RCTs depend on the characteristics of the data and include:
  - For dichotomous (binary) outcome data, logistic regression (e.g., to predict sustained virological response after receipt of peginterferon alfa-2a for hepatitis C^[1]) and other methods can be used.
  - For continuous outcome data, analysis of covariance (e.g., for changes in blood lipid levels after receipt of atorvastatin after acute coronary syndrome^[2]) tests the effects of predictor variables.
  - For time-to-event outcome data that may be censored, survival analysis (e.g., Kaplan–Meier estimators and Cox proportional hazards models for time to coronary heart disease after receipt of hormone replacement therapy in menopause^[3]) is appropriate.

↑ Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001). "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial". Lancet 358 (9286): 958–65. doi:10.1016/S0140-6736(01)06102-5. PMID 11583749.
↑ Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001). "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial". J Am Med Assoc 285 (13): 1711–8. doi:10.1001/jama.285.13.1711. PMID 11277825. http://jama.ama-assn.org/cgi/content/full/285/13/1711.
↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators (2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial". J Am Med Assoc 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397. http://jama.ama-assn.org/cgi/content/full/288/3/321.